Mesoblast (MESO) Stock Overview
Engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for MESO from our risk checks.
MESO Community Fair Values
Create NarrativeSee what 9 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Mesoblast Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$15.85 |
| 52 Week High | AU$21.50 |
| 52 Week Low | AU$9.61 |
| Beta | 0.85 |
| 1 Month Change | -6.71% |
| 3 Month Change | -11.30% |
| 1 Year Change | 17.67% |
| 3 Year Change | 136.57% |
| 5 Year Change | -15.06% |
| Change since IPO | 94.44% |
Recent News & Updates
Recent updates
Shareholder Returns
| MESO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | -2.6% | -1.2% |
| 1Y | 17.7% | 23.8% | 19.2% |
Return vs Industry: MESO underperformed the US Biotechs industry which returned 23.8% over the past year.
Return vs Market: MESO underperformed the US Market which returned 19.2% over the past year.
Price Volatility
| MESO volatility | |
|---|---|
| MESO Average Weekly Movement | 8.2% |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: MESO has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: MESO's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 81 | Silviu Itescu | www.mesoblast.com |
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company’s proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Remestemcel-L, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as ulcerative colitis and Crohn's disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease.
Mesoblast Limited Fundamentals Summary
| MESO fundamental statistics | |
|---|---|
| Market cap | US$1.97b |
| Earnings (TTM) | -US$94.37m |
| Revenue (TTM) | US$65.38m |
Is MESO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MESO income statement (TTM) | |
|---|---|
| Revenue | US$65.38m |
| Cost of Revenue | US$88.62m |
| Gross Profit | -US$23.23m |
| Other Expenses | US$71.14m |
| Earnings | -US$94.37m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.073 |
| Gross Margin | -35.53% |
| Net Profit Margin | -144.33% |
| Debt/Equity Ratio | 22.1% |
How did MESO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/06 23:36 |
| End of Day Share Price | 2026/03/06 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Mesoblast Limited is covered by 21 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| John Hester | Bell Potter |
| Stuart Roberts | Bell Potter |
| Matthew Prior | BofA Global Research |